HIMS · NYSE · STOCK
Hims & Hers Health (HIMS) Stock Analysis
$28.61
52W $13.74 – $65.30
52/100
$6.28B
-46.1
2.42
Is HIMS Bullish or Bearish?
Mixed.
Innellis AI committee rates Hims & Hers Health (HIMS) Watch with a composite score of 52/100
, based on 6 analysts with 33% agreement.
Last updated August 17, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.96 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.04 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — price-to-book of 13.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 32.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price-to-book of 13.7x prices in significant intangible value — Value
- ROE of only -2.5% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 1.80 adds balance-sheet risk to the value case — Value
- 2 consecutive earnings misses -- execution concerns — Growth
- MACD histogram negative -- bearish momentum — Technical
- High leverage (debt-to-equity 1.80) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 17, 2026
Overall Committee Score
52/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 96%
of 192 Healthcare peers
Value Analyst
bearish
32
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 13.7x prices in significant intangible value
Growth Analyst
bullish
63
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 32.8% YoY -- genuine top-line momentum
− 2 consecutive earnings misses -- execution concerns
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.80) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
51
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
− News sentiment is negative (-0.20 across 75 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Investment Thesis Evolution
Committee score moved marginally from 52.0 to 52.0.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Portfolio Manager: +1 bearish signal(s).
Comparing 2026-08-16 to 2026-08-17 (1 day apart).
Technical Analysis
RSI (14)
37.8
Neutral
MACD Histogram
-0.134
Bearish Momentum
Trend Direction
Sideways
Weekly: Sideways
Market Structure
Hh Hl
Support
$24.12
Resistance
$31.85
Bollinger %B
0.27
Inside Bands
Price vs Moving Averages
EMA 9
$29.79
Below
EMA 21
$30.52
Below
EMA 50
$30.50
Below
EMA 200
$31.06
Below
Fundamental Analysis
Valuation
65
Growth
29
Profitability
65
Financial Health
6
Cash Flow
70
Valuation
P/E Ratio
-46.1×
P/B Ratio
20.13×
PEG Ratio
1.10
Dividend Yield
0.00%
52W High
$65.30
52W Low
$13.74
Quality & Growth
ROE
2373.0%
ROA
595.7%
Gross Margin
6468.2%
Operating Margin
-359.4%
Revenue Growth YoY
—
Debt / Equity
4.77
AI Fundamental Assessment
P/E ratio of -46.1 (inexpensive relative to a 15-40x range); Price-to-book of 20.1x; PEG ratio of 1.1 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 23.7%; Return on assets of 6.0%; Net margin of -5.5%; Gross margin of 64.7%; Current ratio of 0.93 (tight short-term liquidity); Debt-to-equity of 4.77; Free cash flow per share is positive (0.39); Most recent quarter missed estimates by 599.3%; 2 consecutive earnings misses; EPS growth accelerating (-337.5% -> +47.4% QoQ); Average YoY EPS growth of -158.8%; Analyst estimates falling over recent quarters
Get the Full HIMS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →